title: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
abstract: BACKGROUND
  Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone.
  
  
  METHODS
  Updated TROPIC data (cut-off 10 March 2010) were used to compare 2-year survival between treatment groups and assess patient demographics and disease characteristics. Factors prognostic for survival ≥2 years were assessed. Pain and Eastern Cooperative Oncology Group performance status were evaluated in the overall patient population.
  
  
  RESULTS
  Median follow-up was 25.5 months. After 2 years, more patients remained alive following cabazitaxel than mitoxantrone [odds ratio 2.11; 95% confidence interval (CI) 1.33-3.33]. Treatment with cabazitaxel was prognostic for survival ≥2 years. Demographics/baseline characteristics were balanced between treatment arms irrespective of survival. Pain at baseline and pain response were comparable between treatment groups. Average daily pain performance index was lower for cabazitaxel versus mitoxantrone (all cycles; 95% CI -0.27 to -0.01; P = 0.035) and analgesic scores were similar. Grade ≥3 peripheral neuropathies were uncommon and comparable between treatment groups.
  
  
  CONCLUSIONS
  Cabazitaxel prolongs OS at 2 years versus mitoxantrone and has low rates of peripheral neuropathy. Palliation benefits of cabazitaxel were comparable to those of mitoxantrone. The study was registered with www.ClinicalTrials.gov (NCT00417079).
authors.affiliation: Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
authors.forename: A
authors.initials: A
authors.lastname: Bahl
authors.forename: S
authors.initials: S
authors.lastname: Oudard
authors.forename: B
authors.initials: B
authors.lastname: Tombal
authors.forename: M
authors.initials: M
authors.lastname: Ozgüroglu
authors.forename: S
authors.initials: S
authors.lastname: Hansen
authors.forename: I
authors.initials: I
authors.lastname: Kocak
authors.forename: G
authors.initials: G
authors.lastname: Gravis
authors.forename: J
authors.initials: J
authors.lastname: Devin
authors.forename: L
authors.initials: L
authors.lastname: Shen
authors.forename: J S
authors.initials: JS
authors.lastname: de Bono
authors.forename: A O
authors.initials: AO
authors.lastname: Sartor
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D009362:Neoplasm Metastasis / Q000188:drug therapy; D010146:Pain / Q000150:complications / Q000188:drug therapy*; D010147:Pain Measurement; D010166:Palliative Care; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality; D011788:Quality of Life; D013534:Survival; D015996:Survival Rate; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel; D008942:Mitoxantrone
keywords: cabazitaxel; palliative care; prostate cancer; quality of life; symptom relief; treatment response